Literature DB >> 8498674

Plasma inorganic fluoride levels with sevoflurane anesthesia in morbidly obese and nonobese patients.

E J Frink1, T P Malan, E A Brown, S Morgan, B R Brown.   

Abstract

Administration of several of the inhaled anesthetics result in plasma inorganic fluoride concentrations that are higher in obese compared to nonobese patients. Sevoflurane, a new inhaled anesthetic, is metabolized to inorganic fluoride; however, plasma inorganic fluoride levels with sevoflurane anesthesia in obese subjects have not been evaluated. We studied plasma inorganic fluoride concentrations during and after sevoflurane surgical anesthesia in morbidly obese (n = 13, body mass index > 35) and nonobese (n = 10) patients. Sevoflurane anesthesia in 60% nitrous oxide/40% oxygen was administered with a semiclosed circle absorption system. Mean anesthetic duration was 1.4 minimum alveolar anesthetic concentration (MAC) hours (sevoflurane MAC = 2.05%) for both groups. Pre- and postoperative blood urea nitrogen, creatinine, and liver function tests were evaluated. Venous blood samples were obtained during and after anesthesia for plasma inorganic fluoride analysis. In six morbidly obese and nonobese patients arterial blood samples were obtained during and after sevoflurane anesthesia for determining sevoflurane blood concentration. Plasma fluoride concentrations during and after anesthesia did not differ between morbidly obese and non-obese groups. Peak plasma inorganic fluoride ion concentrations were 30 +/- 2 mumol/L (mean +/- SEM) in obese and 28 +/- 2 mumol/L in nonobese patients 1 h after discontinuing anesthesia. The hourly rate of change of fluoride ion concentration in plasma during anesthesia was similar between the groups. The maximal recorded plasma fluoride concentrations were 49 mumol/L in an obese patient and 42 mumol/L in a nonobese patient. Pre- and postoperative hepatic and renal tests did not differ significantly in either group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8498674     DOI: 10.1213/00000539-199376060-00026

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  10 in total

1.  Carpal spasm observed during and after sevoflurane anesthesia.

Authors:  S Watanabe; H Ashimura; S Inomata; M Taguchi; K Shibata
Journal:  J Anesth       Date:  1995-03       Impact factor: 2.078

Review 2.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

3.  Sevoflurane anesthesia for renal transplanted patient-comparison with normal renal function subjects.

Authors:  Tomoki Nishiyama; Masaki Nagase
Journal:  J Anesth       Date:  1995-06       Impact factor: 2.078

4.  Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.

Authors:  Cyrus Ghobadi; Trevor N Johnson; Mohsen Aarabi; Lisa M Almond; Aurel Constant Allabi; Karen Rowland-Yeo; Masoud Jamei; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2011-12-01       Impact factor: 6.447

Review 5.  Sevoflurance: approaching the ideal inhalational anesthetic. a pharmacologic, pharmacoeconomic, and clinical review.

Authors:  L Delgado-Herrera; R D Ostroff; S A Rogers
Journal:  CNS Drug Rev       Date:  2001

Review 6.  Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia.

Authors:  S S Patel; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 7.  Renal toxicity with sevoflurane: a storm in a teacup?

Authors:  B A Gentz; T P Malan
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 8.  Clinical pharmacokinetics of sevoflurane.

Authors:  M Behne; H J Wilke; S Harder
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

9.  Effects of tail fat on recovery times of anesthesia with isoflurane in fat-tailed Iranian Lori-Bakhtiyari lambs.

Authors:  Siavash Sharifi; Abbas Raisi Sarteshnizi; Farangis Sharifi; Elham Yousefian
Journal:  Vet Res Forum       Date:  2015-09-15       Impact factor: 1.054

10.  Role of Sevoflurane on Natural Killer Group 2, Member D-Mediated Immune Response in Non-Small-Cell Lung Cancer: An In Vitro Study.

Authors:  Soeun Jeon; Hae-Kyu Kim; Jae-Young Kwon; Seung-Hoon Baek; Hyun-Su Ri; Ho Jung Choi; Hae-Ryung Cho; Young Shin Lee; Joo-Young Kim; Jinsil Kim; Jaeho Bae; Hyeon-Jeong Lee
Journal:  Med Sci Monit       Date:  2020-11-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.